- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Emerging Bispecifics in Multiple Myeloma: Real-World Insights and Treatment Strategies
Robert M. Rifkin, MD, FACP, discusses how findings from real-world studies on teclistamab and talquetamab presented at the 66th American Society of Hematology Annual Meeting and Exposition reinforce their efficacy and impact on patient outcomes in relapsed/refractory multiple myeloma while panelists discuss how clinicians should prioritize factors such as patient characteristics and treatment history when selecting the most appropriate bispecific therapy for these patients.
EP: 1.Emerging Bispecifics in Multiple Myeloma: Real-World Insights and Treatment Strategies
EP: 2.Navigating Adverse Events in Bispecific Antibody Therapies: Infection Prevention and Management
EP: 3.Proactive CRS Management: The Role of Tocilizumab and Beyond
EP: 4.Expanding Bispecific Therapies to Community Settings: Challenges and Innovations
EP: 5.Leveraging Telehealth and Collaboration for Rural and Community Care Expansion
EP: 6.Streamlining Transitions Between Academic and Community Centers
EP: 7.Optimizing Care Models for Bispecific Antibodies: Strategies for Cost-Effective Delivery
Video content above is prompted by the following:
- Findings from real-world studies on teclistamab and talquetamab presented at 66th American Society of Hematology Annual Meeting and Exposition highlighted their efficacy and patient outcomes outside clinical trials. How do these findings align with clinical trial data, and what differences (if any) stand out to you in the real-world setting?
- Based on the real-world evidence shared for teclistamab and talquetamab, what factors should clinicians prioritize when selecting the appropriate bispecific therapy for patients with relapsed/refractory multiple myeloma?
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD
May 17th 2025Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
Read More
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More
